Annual CFF
$1.11 M
+$903.00 K+446.81%
December 31, 2023
Summary
- As of February 23, 2025, MRKR annual cash flow from financing activities is $1.11 million, with the most recent change of +$903.00 thousand (+446.81%) on December 31, 2023.
- During the last 3 years, MRKR annual CFF has fallen by -$5.63 million (-83.59%).
- MRKR annual CFF is now -98.45% below its all-time high of $71.25 million, reached on December 31, 2018.
Performance
MRKR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$1700.00
-$42.90 K-96.19%
September 30, 2024
Summary
- As of February 23, 2025, MRKR quarterly cash flow from financing activities is $1700.00, with the most recent change of -$42.90 thousand (-96.19%) on September 30, 2024.
- Over the past year, MRKR quarterly CFF has stayed the same.
- MRKR quarterly CFF is now -100.00% below its all-time high of $63.76 million, reached on December 31, 2018.
Performance
MRKR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$100.50 K
-$477.60 K-82.62%
September 30, 2024
Summary
- As of February 23, 2025, MRKR TTM cash flow from financing activities is $100.50 thousand, with the most recent change of -$477.60 thousand (-82.62%) on September 30, 2024.
- Over the past year, MRKR TTM CFF has stayed the same.
- MRKR TTM CFF is now -99.86% below its all-time high of $71.29 million, reached on March 31, 2019.
Performance
MRKR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
MRKR Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +446.8% | 0.0% | 0.0% |
| 3 y3 years | -83.6% | 0.0% | 0.0% |
| 5 y5 years | -98.5% | 0.0% | 0.0% |
MRKR Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -97.9% | +446.8% | -99.7% | -100.0% | -99.8% | +199.8% |
| 5 y | 5-year | -97.9% | +446.8% | -100.0% | +101.7% | -99.8% | +199.8% |
| alltime | all time | -98.5% | >+9999.0% | -100.0% | +100.4% | -99.9% | +199.8% |
Marker Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1700.00(-96.2%) | $100.50 K(-82.6%) |
| Jun 2024 | - | $44.60 K(-9.2%) | $578.10 K(+8.2%) |
| Mar 2024 | - | $49.10 K(+862.7%) | $534.20 K(-51.7%) |
| Dec 2023 | $1.11 M(+446.8%) | $5100.00(-98.9%) | $1.11 M(-10.8%) |
| Sep 2023 | - | $479.30 K(>+9900.0%) | $1.24 M(+63.1%) |
| Jun 2023 | - | $700.00(-99.9%) | $759.30 K(-7.7%) |
| Mar 2023 | - | $620.00 K(+347.3%) | $822.20 K(+306.6%) |
| Dec 2022 | $202.10 K(-99.6%) | $138.60 K(>+9900.0%) | $202.20 K(+217.9%) |
| Sep 2022 | - | $0.00(-100.0%) | $63.60 K(0.0%) |
| Jun 2022 | - | $63.60 K(>+9900.0%) | $63.60 K(-163.2%) |
| Mar 2022 | - | $0.00(0.0%) | -$100.70 K(-100.2%) |
| Dec 2021 | $52.56 M(+680.2%) | $0.00(0.0%) | $52.56 M(-7.1%) |
| Sep 2021 | - | $0.00(-100.0%) | $56.56 M(-3.7%) |
| Jun 2021 | - | -$100.70 K(-100.2%) | $58.74 M(-0.2%) |
| Mar 2021 | - | $52.66 M(+1216.4%) | $58.84 M(+773.6%) |
| Dec 2020 | $6.74 M(+725.0%) | $4.00 M(+83.0%) | $6.74 M(+146.2%) |
| Sep 2020 | - | $2.19 M(>+9900.0%) | $2.74 M(+109.9%) |
| Jun 2020 | - | $0.00(-100.0%) | $1.30 M(0.0%) |
| Mar 2020 | - | $550.00 K(>+9900.0%) | $1.30 M(+59.6%) |
| Dec 2019 | $816.50 K(-98.9%) | $0.00(-100.0%) | $816.50 K(-98.7%) |
| Sep 2019 | - | $753.40 K(>+9900.0%) | $64.58 M(+1.0%) |
| Jun 2019 | - | $0.00(-100.0%) | $63.91 M(-10.4%) |
| Mar 2019 | - | $63.10 K(-99.9%) | $71.29 M(+0.1%) |
| Dec 2018 | $71.25 M(+1146.1%) | $63.76 M(>+9900.0%) | $71.25 M(+852.2%) |
| Sep 2018 | - | $83.10 K(-98.9%) | $7.48 M(+5.8%) |
| Jun 2018 | - | $7.38 M(>+9900.0%) | $7.07 M(+23.3%) |
| Mar 2018 | - | $18.10 K(>+9900.0%) | $5.74 M(+0.3%) |
| Dec 2017 | $5.72 M(-26.6%) | $0.00(-100.0%) | $5.72 M(-0.3%) |
| Sep 2017 | - | -$329.50 K(-105.4%) | $5.74 M(-58.6%) |
| Jun 2017 | - | $6.05 M(>+9900.0%) | $13.86 M(+77.4%) |
| Mar 2017 | - | $0.00(-100.0%) | $7.81 M(+0.3%) |
| Dec 2016 | $7.78 M(-27.8%) | $18.10 K(-99.8%) | $7.78 M(-14.5%) |
| Sep 2016 | - | $7.79 M(>+9900.0%) | $9.11 M(+52.8%) |
| Jun 2016 | - | $0.00(-100.0%) | $5.96 M(-29.3%) |
| Mar 2016 | - | -$25.00 K(-101.9%) | $8.43 M(-21.8%) |
| Dec 2015 | $10.78 M(+372.6%) | $1.34 M(-71.2%) | $10.78 M(+11.9%) |
| Sep 2015 | - | $4.65 M(+88.5%) | $9.63 M(+48.5%) |
| Jun 2015 | - | $2.46 M(+6.0%) | $6.49 M(+54.9%) |
| Mar 2015 | - | $2.33 M(+1077.7%) | $4.19 M(+83.7%) |
| Dec 2014 | $2.28 M(+221.5%) | $197.50 K(-86.8%) | $2.28 M(+10.3%) |
| Sep 2014 | - | $1.50 M(+806.0%) | $2.07 M(+212.2%) |
| Jun 2014 | - | $165.50 K(-60.4%) | $661.90 K(-5.8%) |
| Mar 2014 | - | $418.00 K(-2664.4%) | $702.30 K(-1.0%) |
| Dec 2013 | $709.30 K(-48.3%) | -$16.30 K(-117.2%) | $709.40 K(-43.2%) |
| Sep 2013 | - | $94.70 K(-54.0%) | $1.25 M(-11.9%) |
| Jun 2013 | - | $205.90 K(-51.6%) | $1.42 M(-16.2%) |
| Mar 2013 | - | $425.10 K(-18.7%) | $1.69 M(+23.3%) |
| Dec 2012 | $1.37 M | $522.70 K(+98.0%) | $1.37 M(-8.4%) |
| Sep 2012 | - | $264.00 K(-45.0%) | $1.50 M(+7.3%) |
| Jun 2012 | - | $479.60 K(+352.9%) | $1.40 M(+14.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $105.90 K(-83.7%) | $1.22 M(-20.3%) |
| Dec 2011 | $1.54 M(+90.4%) | $648.60 K(+300.6%) | $1.54 M(+92.1%) |
| Sep 2011 | - | $161.90 K(-47.4%) | $800.00 K(+36.2%) |
| Jun 2011 | - | $307.60 K(-26.5%) | $587.40 K(-48.5%) |
| Mar 2011 | - | $418.40 K(-576.0%) | $1.14 M(+41.3%) |
| Dec 2010 | $807.10 K(-36.1%) | -$87.90 K(+73.4%) | $807.10 K(-43.2%) |
| Sep 2010 | - | -$50.70 K(-105.9%) | $1.42 M(-25.0%) |
| Jun 2010 | - | $860.40 K(+908.7%) | $1.90 M(+61.7%) |
| Mar 2010 | - | $85.30 K(-83.8%) | $1.17 M(-7.1%) |
| Dec 2009 | $1.26 M(+130.4%) | $527.00 K(+24.2%) | $1.26 M(+41.3%) |
| Sep 2009 | - | $424.30 K(+211.3%) | $893.50 K(+64.4%) |
| Jun 2009 | - | $136.30 K(-21.9%) | $543.50 K(-15.4%) |
| Mar 2009 | - | $174.60 K(+10.3%) | $642.50 K(+17.3%) |
| Dec 2008 | $547.90 K(-58.4%) | $158.30 K(+113.1%) | $547.90 K(-48.3%) |
| Sep 2008 | - | $74.30 K(-68.4%) | $1.06 M(-17.0%) |
| Jun 2008 | - | $235.30 K(+194.1%) | $1.28 M(+22.6%) |
| Mar 2008 | - | $80.00 K(-88.0%) | $1.04 M(-21.0%) |
| Dec 2007 | $1.32 M(-9.8%) | $669.20 K(+129.5%) | $1.32 M(+41.6%) |
| Sep 2007 | - | $291.60 K(>+9900.0%) | $930.70 K(-1.2%) |
| Jun 2007 | - | $0.00(-100.0%) | $941.60 K(-29.4%) |
| Mar 2007 | - | $357.50 K(+27.0%) | $1.33 M(-8.7%) |
| Dec 2006 | $1.46 M(+20.5%) | $281.60 K(-6.9%) | $1.46 M(+18.7%) |
| Sep 2006 | - | $302.50 K(-23.0%) | $1.23 M(+30.4%) |
| Jun 2006 | - | $393.00 K(-19.0%) | $944.80 K(+73.4%) |
| Mar 2006 | - | $485.00 K(+841.7%) | $544.80 K(-55.1%) |
| Dec 2005 | $1.21 M(-6.5%) | $51.50 K(+236.6%) | $1.21 M(-13.2%) |
| Sep 2005 | - | $15.30 K(-318.6%) | $1.40 M(-1.8%) |
| Jun 2005 | - | -$7000.00(-100.6%) | $1.42 M(-24.3%) |
| Mar 2005 | - | $1.15 M(+389.4%) | $1.88 M(+44.9%) |
| Dec 2004 | $1.30 M(-35.3%) | $235.80 K(+472.3%) | $1.30 M(-27.1%) |
| Sep 2004 | - | $41.20 K(-90.8%) | $1.78 M(-21.0%) |
| Jun 2004 | - | $449.90 K(-21.2%) | $2.25 M(+9.2%) |
| Mar 2004 | - | $571.30 K(-20.5%) | $2.07 M(+2.9%) |
| Dec 2003 | $2.01 M(+23.5%) | $718.20 K(+39.3%) | $2.01 M(-19.5%) |
| Sep 2003 | - | $515.40 K(+97.8%) | $2.49 M(+60.9%) |
| Jun 2003 | - | $260.60 K(-49.3%) | $1.55 M(-21.4%) |
| Mar 2003 | - | $513.60 K(-57.4%) | $1.97 M(+21.2%) |
| Dec 2002 | $1.63 M(<-9900.0%) | $1.20 M(-381.1%) | $1.63 M(+739.4%) |
| Sep 2002 | - | -$428.50 K(-162.9%) | $193.70 K(-77.2%) |
| Jun 2002 | - | $681.50 K(+304.5%) | $850.00 K(+624.0%) |
| Mar 2002 | - | $168.50 K(-174.0%) | $117.40 K(-4991.7%) |
| Dec 2001 | -$2400.00(-100.3%) | -$227.80 K(-200.0%) | -$2400.00(-101.1%) |
| Sep 2001 | - | $227.80 K(-545.8%) | $209.20 K(+2.0%) |
| Jun 2001 | - | -$51.10 K(-204.9%) | $205.00 K(-62.2%) |
| Mar 2001 | - | $48.70 K(-400.6%) | $542.00 K(-32.9%) |
| Dec 2000 | $807.80 K(-9.1%) | -$16.20 K(-107.2%) | $807.80 K(-2.0%) |
| Sep 2000 | - | $223.60 K(-21.8%) | $824.00 K(+37.2%) |
| Jun 2000 | - | $285.90 K(-9.1%) | $600.40 K(+90.9%) |
| Mar 2000 | - | $314.50 K | $314.50 K |
| Dec 1999 | $888.20 K | - | - |
FAQ
- What is Marker Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Marker Therapeutics?
- What is Marker Therapeutics annual CFF year-on-year change?
- What is Marker Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Marker Therapeutics?
- What is Marker Therapeutics quarterly CFF year-on-year change?
- What is Marker Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Marker Therapeutics?
- What is Marker Therapeutics TTM CFF year-on-year change?
What is Marker Therapeutics annual cash flow from financing activities?
The current annual CFF of MRKR is $1.11 M
What is the all time high annual CFF for Marker Therapeutics?
Marker Therapeutics all-time high annual cash flow from financing activities is $71.25 M
What is Marker Therapeutics annual CFF year-on-year change?
Over the past year, MRKR annual cash flow from financing activities has changed by +$903.00 K (+446.81%)
What is Marker Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of MRKR is $1700.00
What is the all time high quarterly CFF for Marker Therapeutics?
Marker Therapeutics all-time high quarterly cash flow from financing activities is $63.76 M
What is Marker Therapeutics quarterly CFF year-on-year change?
Over the past year, MRKR quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Marker Therapeutics TTM cash flow from financing activities?
The current TTM CFF of MRKR is $100.50 K
What is the all time high TTM CFF for Marker Therapeutics?
Marker Therapeutics all-time high TTM cash flow from financing activities is $71.29 M
What is Marker Therapeutics TTM CFF year-on-year change?
Over the past year, MRKR TTM cash flow from financing activities has changed by $0.00 (0.00%)